Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
  • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
  • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
  • C12P17/185—Heterocyclic compounds containing sulfur atoms as ring hetero atoms in the condensed system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
  • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/02—Nutrients, e.g. vitamins, minerals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P39/00—General protective or antinoxious agents
  • A61P39/06—Free radical scavengers or antioxidants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
  • C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
  • C12P1/04—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using bacteria
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
  • C12P13/00—Preparation of nitrogen-containing organic compounds
  • C12P13/001—Amines; Imines
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
  • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
  • C12P17/02—Oxygen as only ring hetero atoms
  • C12P17/06—Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
  • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
  • C12P17/10—Nitrogen as only ring hetero atom
  • C12P17/12—Nitrogen as only ring hetero atom containing a six-membered hetero ring
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
  • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
  • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
  • C12P17/167—Heterorings having sulfur atoms as ring heteroatoms, e.g. vitamin B1, thiamine nucleus and open chain analogs
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
  • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
  • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
  • C12P17/182—Heterocyclic compounds containing nitrogen atoms as the only ring heteroatoms in the condensed system
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
  • C12P7/00—Preparation of oxygen-containing organic compounds
  • C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
  • C12P7/22—Preparation of oxygen-containing organic compounds containing a hydroxy group aromatic

Definitions

• the present invention relates to a method for producing beneficial compounds for use in a medicament and/or a nutritional supplement. More particularly the present invention relates to a method for producing beneficial compounds derived from a once living source.
• ROS reactive oxygen species
• ROS are byproducts of the normal metabolic processes of living organisms. ROS include oxygen-derived free radicals and non-radical derivatives that can cause oxidative damage to biological structures. ROS have also been shown to play a role in the aging process and a number of pathological syndromes such as, for example, diabetes. However, oxidative damage caused by ROS can be reduced or prevented through a number of mechanisms such as, for example, the use of antioxidants that can react directly with ROS in the body.
• Green tea ⁇ Camellia sinensis has been found to contain significant levels of polyphenols which have been found to be particularly potent antioxidants.
• green tea polyphenols have been associated with heart disease and cancer prevention and may effectively reduce the incidence and severity of rheumatoid arthritis.
• green tea also contains alkaloids including caffeine, theobromine, and theophylline which provide a stimulant effect that may negatively impact a variety of neurological and cardiovascular processes.
• alkaloids including caffeine, theobromine, and theophylline which provide a stimulant effect that may negatively impact a variety of neurological and cardiovascular processes.
• Melatonin a hormone naturally produced in the body by the pineal gland, is another particularly important antioxidant.
• One of the potential causes of age-related brain deterioration is toxic free radical compounds that are produced during aerobic metabolism.
• Vitamin E and Vitamin C aid in protecting the brain from oxidative stress by scavenging toxic free radicals.
• B vitamins are essential for normal metabolism and enzyme function in the human body.
• B vitamins are the critical structural components of several key coenzymes such as, for example, thiamine pyrophosphate, flavin mononucleotide, flavin adenine dinucleotide, pyridoxal pyrophosphate, nicotinamide adenine dinucleotide, nicotinamide adenine dinucleotide phosphate, biotin, folic acid, cobalamin, coenzyme A and CoQ-10, and play a vital role in the breakdown of carbohydrates, fats and proteins, the synthesis of amino acids and other substances that comprise DNA and RNA, formation of red blood cells, the promotion of growth and development, and the production of energy.
• Chinese gold coin weed or herb that may be used to treat or prevent stone formation in the gall bladder.
• Chinese gold coin weed alternatively known as herba lysimachiae, jinquiancao or yellow willow herb, has been used for thousands of years in China to treat liver, gallbladder, kidney and urinary bladder aliments.
• This herb contains phenolic ingredients, sterols, flavinoids, amino acids, tannin, volatile oils, choline and potassium salts.
• the whole plant has cholagogue (bile stimulating), depurative and diuretic properties that promote discharge of bile from the common bile duct which may soften and promote discharge of bile stones from the gallbladder.
• Bioavailability of a particular compound determines the body's ability to take up or absorb the compound and utilize the compound in physiological and metabolic processes. In general, if the bioavailability of a particular compound is low a larger dosage of the compound must be ingested to achieve the desired effect on the body. However, ingesting higher doses of some of compounds may cause undesirable side effects which may negatively impact other metabolic and physiological processes.
• a natural (once living) source is comprised of dynamic, complex processes where in each molecule some of the atoms have electrons that are aligned and mass accelerated to allow the generation of coherent light. It has been shown that this body of light is found only in the DNA from once living source nutrients which in turn prevents cellular DNA degradation.
• beneficial compounds such as, for example, polyphenols, melatonin, vitamin B derived coenzymes, and herba lysimachiae which are derived from a natural source.
• beneficial compounds that are derived from a once living source that have an improved level of bioavailability.
• a method of producing such beneficial compounds for use in a medicament or a nutritional supplement is provided.
• a general object of the invention is to provide a method for producing beneficial compounds for use in a medicament or a nutritional supplement.
• a particular object of the invention is to provide a method for producing compounds derived from a once-living source that have improved bioavailability.
• a more specific object of this invention is to overcome one or more of the problems described above.
• the general object of the invention can be attained, at least in part, through a method for producing probiotically derived beneficial compounds including dispersing a microbiological culture media including at least one live probiotic organism, and at least one nutraceutical and/or at least one nutritive agent in distilled water to form a broth, incubating the broth at a predetermined temperature for a select period of time to induce probiotic activity; adding organic ethanol to halt the probiotic activity, and separating the desired compound from the broth.
• the general art has generally failed to provide a method for producing beneficial compounds such as, for example, polyphenols, melatonin, vitamin B derived coenzymes and herba lysimachiae that is effective as desired in satisfying one or more of the above-identified performance criteria. Additionally, the prior art has generally failed to provide a method for deriving a beneficial compound from a once-living source such as by feeding a probiotic organism a nutraceutical or nutritive agent and separating the beneficial compound from the waste byproduct. Moreover, the prior art has generally failed to identify a microbiological culture media that can be utilized to produce such beneficial compounds.
• beneficial compounds such as, for example, polyphenols, melatonin, vitamin B derived coenzymes and herba lysimachiae that is effective as desired in satisfying one or more of the above-identified performance criteria. Additionally, the prior art has generally failed to provide a method for deriving a beneficial compound from a once-living source such as by feeding a probiotic organism a nutrac
• the invention further comprehends a microbiological culture media for producing such beneficial compounds including: at least one live probiotic organism; and at least one nutritive or nutraceutical agent.
• the present invention provides a method for producing a probiotically derived beneficial compound for use in a medicament or a nutritional supplement such as by feeding a probiotic organism a nutraceutical or nutritive agent, harvesting the waste byproducts and separating the beneficial compound from the waste byproducts.
• the present invention further provides beneficial compounds derived from a once living source having improved bioavailability and suitable for use in a medicament or a nutritional supplement.
• green tea also includes significant levels of caffeine and theobromine.
• increased consumption of green tea provides increased levels of polyphenols to scavenge free radicals and other reactive oxygen species (ROS) from the body
• ROS reactive oxygen species
• increased consumption of green tea also provides increased consumption of caffeine and theobromine which can have an undesirable impact on the nervous and cardiovascular systems.
• Other synthetically derived compounds may not be in the best form for absorption by the body.
• CoQ-IO is a B vitamin derived coenzyme that is a vital component of the mitochondria of all cells, particularly those of the heart and liver, and is co-factor in the transport of electrons between cells.
• CoQ-IO is a potent antioxidant which scavenges free radicals and regenerates vitamin E in the cell membrane which may promote improved cardiovascular and immune system health.
• most commercially available CoQ-IO supplements contain oxidized CoQ-IO or UVI-quinone. When such oxidized CoQ-IO is ingested the body must expend energy to transform UVI-quinine to UVI-quinol or reduced CoQ-IO before the cells can absorb and utilize the reduced CoQ-IO in regenerative and electron transport processes.
• Other beneficial compounds in their natural forms may simply be too difficult for the human body to digest in order to obtain the most desirable dosage. For example, Chinese gold coin weed or herba lysimachiae is an herb that is difficult for the human body to digest. Thus, repeated doses of the compound are required over extended periods of time in order to achieve the desired result.
• beneficial compounds are available in their synthetic form due to the unavailability of or cost of obtaining the natural compound.
• melatonin a hormone produced by and derived from the pineal gland of various animal species such as, for example, bears, is widely available in the synthetic form due to cost of extracting the hormone from pineal glands and public outcry against sacrificing living animals to obtain the hormone.
• a beneficial compound for use in a medicament or a nutritional supplement is derived from a once living source.
• beneficial compound can be derived from a microbiological culture media including at least one live probiotic organism and at least one nutraceutical or nutritive agent.
• the at least one probiotic organism can be selected from Lactobacillus species, Bifidobacterium species, Enterococcus species, generally accepted as safe (GRAS) Streptococcus thermophilus, and combinations thereof.
• the microbiological culture media can include at least one live probiotic organism selected from Lactobacillus species and at least one live probiotic organism selected from Bifidobacterium species.
• suitable Lactobacillus species include, but are not limited to, L. acidophilus, L. paracasei, L. fermentum, L. rhamnosus, L.
• Bifidobacterium species include, but are not limited to, B. bifidum, B. breve, B. infantis, B. longum, B. lactis and combinations thereof.
• suitable Enterococcus species include, but are not limited to, E. faceum, E. faecalis, and combinations thereof.
• nutraceutical or nutritive agents can be utilized in the microbiological culture media of the invention, suitable nutraceutical or nutritive agents should contribute to the production of the desired beneficial compound as well as to the stability of the microbiological media.
• the particular nutraceutical or nutritive agent or agents utilized in the microbiological culture media will depend upon the beneficial compound to be derived. For example, if the beneficial compound to be derived from the microbiological culture media is stabilized dihydrolipoic acid (DHLA), the nutritive agent contained in the microbiological media may be tumeric rhizome ⁇ curcuma longa).
• DHLA dihydrolipoic acid
• the nutraceutical or nutritive agent utilized in the microbiological culture media may be a synthetic form of the beneficial compound to be derived or may be naturally occurring source of the beneficial compound , such as, for example, a plant or herb, which must be processed in order to isolate the beneficial compound.
• a beneficial compound for use in a medicament or a nutritional supplement may be derived by preparing a microbiological culture including at least one live probiotic organism and at least one nutraceutical or nutritive agent, incubating the culture to initiate probiotic activity, harvesting a waste byproduct of the probiotic activity, and separating a beneficial compound from the waste byproduct.
• DHLA is typically produced within the body through the redox conversion of lipoic acid or alpha-lipoic acid (ALA) during normal metabolic activity.
• ALA alpha-lipoic acid
• the body generally only produces an amount of DHLA sufficient to assist in metabolic function.
• DHLA has been shown, at least in part, to be an effective antioxidant and chelating agent that can be utilized to scavenge reactive nitrogen species (RNS) and reactive oxygen species (ROS) such as, for example, singlet oxygen, that can contribute to a number of degradative pathological syndromes such as diabetes, glaucoma, atherosclerosis, and other neuropathies.
• RNS reactive nitrogen species
• ROS reactive oxygen species
• DHLA has also been found, at least in part, to be effective to prevent or repair oxidative damage in cells and to regenerate certain important nutrients in the body such as, for example, vitamins C and E.
• ALA which is derived from non-living sources which have no DNA and may induce cellular DNA degradation especially in long term use.
• ALA used in the cell to make minimal amounts of DHLA is not beneficial for long term use.
• DHLA derived from once living sources includes DNA which is known to support cell DNA.
• stabilized dihydrolipoic acid (DHLA) for use in a medicament or nutritional supplement is derived from a once living source.
• the stabilized DHLA compound can be derived from a microbiological culture media including at least one live probiotic organism, i?-lipoic acid, and at least one nutraceutical or nutritive agent.
• Synthetic sources of alpha-lipoic acid generally include, in equal amounts, /?-lipoic acid and S-lipoic acid.
• ALA containing S-lipoic acid possesses pro-inflammatory properties which results in the formation of undesirable compounds and may detract from the function of ALA.
• i?-lipoic acid is utilized in the microbiological culture media.
• nutraceuticals or nutritive agents can be utilized in the microbiological culture media of the invention, suitable nutraceuticals or nutritive agents should contribute to the production of DHLA as well as contribute to the stability of the microbiological media.
• the nutraceutical or nutritive agent can be turmeric rhizome (curcuma long ⁇ ).
• the microbiological culture media of the present invention can include about 40 composition weight percent of a paste including at least one live probiotic organism, about 20 composition weight percent /?-lipoic acid, and about 40 composition weight percent of turmeric rhizome (curcuma long ⁇ ) nutritive agent.
• the stabilized dihydrolipoic acid (DHLA) of the present invention may be prepared by dispersing a microbiological culture media including at least one live probiotic organism, ⁇ -lipoic acid and at least one nutritive agent in distilled water to form a broth.
• the broth is then incubated at a predetermined temperature such as, for example, about 35 0 C to about 4O 0 C, for a select period of time such as, for example, about 72 to about 168 hours (i.e. about 3 to about 7 days) to induce probiotic activity.
• organic ethanol is added to the broth to halt the probiotic activity and preserve the synthesized compounds.
• Green Tea Polyphenols [0038] As discussed above, green tea includes significant amounts of polyphenol compounds which have been found to be particularly potent antioxidant compounds which may effectively be utilized to reduce the incidence and severity of rheumatoid arthritis and heart disease and may inhibit or prevent certain cancers. However, green tea also includes significant levels of caffeine which when ingested can have an undesirable effect on neurological and cardiovascular processes. Furthermore, polyphenol compounds ingested via the consumption of green tea my not have an as high as desired level of bioavailability.
• polyphenol compounds with improved bioavailability and increased potency may be derived from a microbiological culture containing at least one live probiotic organism selected from Lactobacillus species, Bifidobacterium species, Enterococcus species, generally accepted as safe (GRAS) Streptococcus thermophilus, and combinations thereof, green tea leaves and at least one nutraceutical or nutritive agent.
• GRAS safe Streptococcus thermophilus
• the resulting polyphenol compounds contain minimal amounts of associated compounds such as, for example, caffeine which is consumed during the incubation process.
• Suitable nutritive or nutraceutical agents for use in a microbiological culture to produce polyphenol compounds having improved potency and bioavailability include, for example, green tea (Camellia sinensis) in whole leaf, chopped leaf or powdered form, one or more polyphenol concentrates and combinations thereof.
• suitable polyphenol concentrates for use in the present invention include epigallocatechin-3-gallate, epigallocatechin, epicatechin-3-gallate, epicatechin, catechin-3- galate, catechin and combinations thereof.
• the improved polyphenol compounds of the present invention may be prepared by dispersing a microbiological culture media including at least one live probiotic organism, and at least one nutritive agent in distilled water to form a broth.
• the broth is then incubated at a predetermined temperature such as, for example, about 35 0 C to about 40 0 C, for a select period of time such as, for example, about 96 to about 144 hours (i.e. about 4 to about 6 days) to induce probiotic activity.
• organic ethanol is added to the broth to halt the probiotic activity and preserve the synthesized compounds.
• the desired polyphenol compounds can be separated from the broth and used to prepare a medicament or nutritional supplement.
• B vitamins and their associated coenzymes are critical components in metabolic processes within the human body. Such B vitamins and their associated coenzymes are essential in order for the body to produce the necessary energy to conduct everyday life. Generally, an individual may consume sufficient levels of B vitamins or manufacture them in the small intestines. However, in cases of bowel disease, extreme stress, etc., a B supplement may be needed.
• high energy forms of the B vitamins and/or their associated end-chain coenzymes may be derived from a microbiological culture including at least one live probiotic organism selected from Lactobacillus species, Bifidobacterium species, Enterococcus species, generally accepted as safe (GRAS) Streptococcus thermophilus, and combinations thereof, a starting material including at least one B vitamin source, and at least one nutritive agent.
• GRAS safe Streptococcus thermophilus
• B vitamins and/or B vitamin derived coenzymes may be produced individually or in combination.
• the method of the present invention may be utilized to produce, for example, 5-methyltetrahydofolate, 5-deoxyadenosylcobalamin, pyridoxal-5-phosphate, coenzyme A, inositol hexanicotinamide, riboflavin-5-phosphate, thiamin cocarboxylase, inositol, choline, biotin and combinations thereof.
• Suitable starting materials include, for example, one or more sources of folic acid, vitamin B12, vitamin B6, vitamin B5, vitamin B3, vitamin B2, vitamin Bl, inositol, choline, biotin and combinations thereof.
• the microbiological culture may include a nutritive agent selected from the family of nutritional yeast species.
• a nutritive agent selected from the family of nutritional yeast species.
• One suitable nutritional yeast species for use in conjunction with the present invention includes the species Saccharomyces cerevisiae.
• the high energy B vitamins and/or B vitamin derived coenzymes of the present invention may be prepared by dispersing a microbiological culture media including at least one live probiotic organism, at least one source of at least one B vitamin, and at least one nutritive agent in distilled water to form a broth.
• the broth is then incubated at a predetermined temperature such as, for example, about 35 0 C to about 4O 0 C, for a select period of time such as, for example, about 96 to about 240 hours (i.e. about 4 to about 10 days) to induce probiotic activity.
• organic ethanol is added to the broth to halt the probiotic activity and preserve the synthesized compounds.
• the desired B vitamins and/or B vitamin derived coenzymes can be separated from the broth and used to prepare a medicament or nutritional supplement.
• Reduced CoO-10 UVI-quinol
• reduced CoQ-10 may be derived from a microbiological culture including at least one live probiotic organism selected from Lactobacillus species, Bifidobacterium species, Enterococcus species, generally accepted as safe (GRAS) Streptococcus thermophilus, and combinations thereof and oxidized CoQ-10 (UVI-quinone) nutraceutical agent.
• GRAS safe Streptococcus thermophilus
• the microbiological culture of the present invention may further include one or more nutritive agents.
• Such nutritive agent or agents may be used to support the probiotic organism and/or improve the overall UVI-quinol yield.
• One such nutritive agent that is suitable for use in a microbiological culture containing at least one live probiotic organism and oxidized CoQ-10 is turmeric rhizome ⁇ curcuma longa) nutritive agent.
• UVI-quinol may be prepared by dispersing a microbiological culture media including at least one live probiotic organism and UVI- quinone nutraceutical agent in distilled water to form a broth.
• the broth is then incubated at a predetermined temperature such as, for example, about 35 0 C to about 4O 0 C, for a select period of time such as, for example, about 168 to about 196 hours (i.e. about 7 to about 8.25 days) to induce probiotic activity.
• a select period of time such as, for example, about 168 to about 196 hours (i.e. about 7 to about 8.25 days) to induce probiotic activity.
• organic ethanol is added to the broth to halt the probiotic activity and preserve the synthesized compounds.
• the desired UVI-quinol can be separated from the broth and used to prepare a medicament or nutritional supplement.
• Chinese Gold Coin Herba lvsimachiae
• a nano-form of Chinese gold coin herb that is more readily absorbable by the human body may be derived from a microbiological culture including at least one live probiotic organism selected from Lactobacillus species, Bifidobacterium species, Enterococcus species, generally accepted as safe (GRAS) Streptococcus thermophilus, and combinations thereof and Chinese gold coin herb nutritive agent.
• the Chinese gold coin herb nutritive agent may be included in the microbiological culture in a whole, chopped and/or powdered form.
• the nano-form of herba lysimachiae may be prepared by dispersing a microbiological culture media including at least one live probiotic organism and herba lysimachiae nutritive agent in distilled water to form a broth.
• the broth is then incubated at a predetermined temperature such as, for example, about 35°C to about 4O 0 C, for a select period of time such as, for example, about 24 to about 72 hours (i.e. about 1 to about 3 days) to induce probiotic activity.
• organic ethanol is added to the broth to halt the probiotic activity and preserve the synthesized compounds.
• the desired nano-form of herba lysimachiae can be separated from the broth and used to prepare a medicament or nutritional supplement.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Wood Science & Technology (AREA)
• Zoology (AREA)
• General Health & Medical Sciences (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biochemistry (AREA)
• Biotechnology (AREA)
• Genetics & Genomics (AREA)
• General Engineering & Computer Science (AREA)
• Microbiology (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Mycology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Hematology (AREA)
• Diabetes (AREA)
• Nutrition Science (AREA)
• Toxicology (AREA)
• Obesity (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Anti-Oxidant Or Stabilizer Compositions (AREA)
• Coloring Foods And Improving Nutritive Qualities (AREA)
• Medicines Containing Plant Substances (AREA)

Priority Applications (5)

Applications Claiming Priority (2)

Publications (2)

Family

ID=36648071

Family Applications (1)

Country Status (7)

Families Citing this family (4)

Family Cites Families (17)

• 2005
  • 2005-01-03 US US11/028,272 patent/US8530209B2/en not_active Expired - Fee Related
  • 2005-12-30 CN CN2005800479299A patent/CN101155923B/zh not_active Expired - Fee Related
  • 2005-12-30 EP EP05855980A patent/EP1836310A4/en not_active Withdrawn
  • 2005-12-30 WO PCT/US2005/047497 patent/WO2006074094A2/en not_active Ceased
  • 2005-12-30 CA CA2594187A patent/CA2594187C/en not_active Expired - Fee Related
  • 2005-12-30 MX MX2007008155A patent/MX2007008155A/es active IP Right Grant
  • 2005-12-30 CA CA2830842A patent/CA2830842A1/en not_active Abandoned
  • 2005-12-30 JP JP2007549664A patent/JP2008526767A/ja active Pending
• 2013
  • 2013-09-09 US US14/021,951 patent/US20140011244A1/en not_active Abandoned

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events